These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29390996)

  • 21. Access to essential medicines for sexual and reproductive health care: the role of the pharmaceutical industry and international regulation.
    Cottingham J; Berer M
    Reprod Health Matters; 2011 Nov; 19(38):69-84. PubMed ID: 22118143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
    Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
    BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abortion in Nepal: perspectives of a cross-section of sexual and reproductive health and rights professionals.
    Rogers C; Sapkota S; Tako A; Dantas JAR
    BMC Womens Health; 2019 Feb; 19(1):40. PubMed ID: 30808340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early medical abortion in India: three studies and their implications for abortion services.
    Coyaji K
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):191-4. PubMed ID: 10846337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Essential medicines and human rights: what can they learn from each other?
    Hogerzeil HV
    Bull World Health Organ; 2006 May; 84(5):371-5. PubMed ID: 16710546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accountability for sexual and reproductive health and rights in development practice: building synergies.
    Barragués Fernández A
    Sex Reprod Health Matters; 2020 Dec; 28(1):1848399. PubMed ID: 33300849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to Medicines in Times of Conflict: Overlapping Compliance and Accountability Frameworks for Syria.
    Leyh BM; Gispen ME
    Health Hum Rights; 2018 Jun; 20(1):237-250. PubMed ID: 30008566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early medical abortion--available and safe.
    de Costa CM; Carrette M
    Med J Aust; 2012 Sep; 197(5):257-8. PubMed ID: 22938106
    [No Abstract]   [Full Text] [Related]  

  • 29. In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments.
    Rehnström Loi U; Prata N; Grossman A; Lavelanet A; Williams N; Ganatra B
    Reprod Health; 2023 Jan; 20(Suppl 1):20. PubMed ID: 36694182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical methods of early abortion in developing countries. Consensus statement. The Population Council.
    Contraception; 1998 Nov; 58(5):257-9. PubMed ID: 9883380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of abortion is now: Mifepristone by mail and in-clinic abortion access in the United States.
    Mark A; Foster AM; Perritt J
    Contraception; 2021 Jul; 104(1):38-42. PubMed ID: 33844980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Research on regimens for early medical abortion.
    von Hertzen H
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):133-6, 150. PubMed ID: 10846322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
    Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interpreting International Humanitarian Law to Guarantee Abortion and Other Sexual and Reproductive Health Services in Armed Conflict.
    Zampas C; Brown R; Afulukwe O
    Health Hum Rights; 2024 Jun; 26(1):31-44. PubMed ID: 38933223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
    Faunce TA
    Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts?
    Hogerzeil HV; Samson M; Casanovas JV; Rahmani-Ocora L
    Lancet; 2006 Jul; 368(9532):305-11. PubMed ID: 16860700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
    Gatter M; Cleland K; Nucatola DL
    Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reconceptualizing safe abortion and abortion services in the age of abortion pills: A discussion paper.
    Berer M
    Best Pract Res Clin Obstet Gynaecol; 2020 Feb; 63():45-55. PubMed ID: 31494046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
    Baird DT; Sukcharoen N; Thong KJ
    Hum Reprod; 1995 Jun; 10(6):1521-7. PubMed ID: 7593528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
    Goldstone P; Michelson J; Williamson E
    Med J Aust; 2012 Sep; 197(5):282-6. PubMed ID: 22938126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.